ストックスクリーナーアプリを入手
166.08
0.04%
-0.06
プレマーケット:
167.15
1.07
+0.64%
前日終値:
$166.14
開ける：
$167.15
24時間の取引高:
3.06M
Relative Volume:
0.97
時価総額：
$257.57B
収益：
$60.48B
当期純損益:
$10.40B
株価収益率:
49.88
EPS:
3.3297
ネットキャッシュフロー:
$8.05B
1週間 パフォーマンス:
+3.69%
1か月 パフォーマンス:
+3.74%
6か月 パフォーマンス:
-11.86%
1年 パフォーマンス:
+115.49%
1日の値動き範囲:
$165.54
$167.83
1週間の範囲:
$160.71
$167.83
52週間の値動き範囲:
$72.89
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
166.08 | 248.41B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,152.93 | 994.49B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
269.99 | 640.02B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
263.96 | 454.36B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
146.87 | 355.10B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
140.37 | 260.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2025-10-27 | 再開されました | Jefferies | Buy |
| 2025-10-16 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-02-13 | アップグレード | UBS | Neutral → Buy |
| 2025-02-12 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-20 | アップグレード | UBS | Sell → Neutral |
| 2024-11-06 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-09-13 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-16 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-02-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Sell |
| 2024-01-03 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-09-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-07-12 | アップグレード | UBS | Neutral → Buy |
| 2023-07-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-04-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2022-09-15 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | アップグレード | Argus | Hold → Buy |
| 2022-06-14 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-11 | アップグレード | DZ Bank | Sell → Hold |
| 2021-12-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-12 | 再開されました | JP Morgan | Overweight |
| 2021-04-12 | ダウングレード | Argus | Buy → Hold |
| 2021-03-16 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | アップグレード | UBS | Neutral → Buy |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-12-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | アップグレード | UBS | Sell → Neutral |
| 2020-11-11 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2019-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-10-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-02 | ダウングレード | UBS | Neutral → Sell |
| 2019-02-05 | 開始されました | Exane BNP Paribas | Outperform |
| 2019-01-25 | アップグレード | Shore Capital | Hold → Buy |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-08-16 | ダウングレード | Jefferies | Buy → Hold |
| 2018-03-19 | アップグレード | Jefferies | Hold → Buy |
| 2018-02-06 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-05 | 繰り返されました | Bernstein | Outperform |
| 2018-01-18 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-12-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | アップグレード | Bernstein | Mkt Perform → Outperform |
すべてを表示
Astrazeneca Plc (AZN) 最新ニュース
AstraZeneca stock holds steady amid licensing deal for novel Lp(a) inhibitor - ad-hoc-news.de
AstraZeneca COPD Drug Cuts Exacerbations as FDA Priority Review Nears - Yahoo Finance
AstraZeneca stock falls as Etcamah trial setback clouds oncology outlook - ad-hoc-news.de
AstraZeneca: The $5 Billion Pipeline Hole Did Not Stay Open Long (NYSE:AZN) - Seeking Alpha
AstraZeneca breast cancer drug fails late-stage trial goal By Investing.com - Investing.com Nigeria
AstraZeneca's breast cancer pill fails in late-stage trial - Reuters
AstraZeneca's Etcamah fails in late-stage trial as first-line breast cancer treatment - Seeking Alpha
AstraZeneca stock falls after Etcamah trial setback despite strong oncology pipeline - ad-hoc-news.de
AstraZeneca Says Late-Stage Etcamah Breast-Cancer Trial Misses Main Goal - marketscreener.com
AstraZeneca breast cancer drug fails late-stage trial goal - investing.com
AstraZeneca Says Breast Cancer Pill Fails in Key Study - Bloomberg.com
AstraZeneca : Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer - marketscreener.com
Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer - AstraZeneca
Jim Cramer Says He Is Not Going to Put His Money on AstraZeneca (AZN) - Yahoo Finance
AstraZeneca Halts Early Lung Cancer Imaging Trial: What Investors Should Watch Next - TipRanks
Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca - Yahoo Finance
AstraZeneca stock gains as analysts see upside ahead of next earnings - ad-hoc-news.de
AstraZeneca stock heads into the open after a modest London gain - ad-hoc-news.de
AstraZeneca stock heads into the open after a 0.93% gain - ad-hoc-news.de
Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? - Yahoo Finance
AstraZeneca’s New Cholesterol Combo Trial Could Reshape Its Heart-Health Portfolio - TipRanks
Berenberg Notes AstraZeneca's 'Stellar' Tozorakimab Late-stage Data; Buy Retained - marketscreener.com
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff - Zacks Investment Research
AstraZeneca's $5bn drug promise is no 'buy' signal for Deutsche - Proactive financial news
AstraZeneca stock edges higher as Deutsche Bank sticks to Sell after COPD data - ad-hoc-news.de
AstraZeneca stock gains new RBC and Berenberg backing on COPD trial success - ad-hoc-news.de
AstraZeneca PLC : Gets a Sell rating from Deutsche Bank - marketscreener.com
Can AstraZeneca (LSE:AZN) Stock Extend Its Rally On A Fresh Wave Of Oncology Approvals? - Kalkine Media
AstraZeneca stock heads into the open after a modest September 9, 2026 gain - ad-hoc-news.de
AstraZeneca stock heads into the open after a 2.0 percent drop - ad-hoc-news.de
Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)? - Yahoo Finance
AstraZeneca Falls 1.3% Despite a 34% COPD Breakthrough - GuruFocus
AstraZeneca Advances TROP2 Testing Standard in Key Lung Cancer Study - TipRanks
AstraZeneca slips Wednesday, underperforms market - MarketWatch
AstraZeneca COPD data back Citi's $7b peak sales case - Proactive Investors
AstraZeneca stock gains analyst support as RBC sets 14,500p target - ad-hoc-news.de
RBC Capital Markets Initiates AstraZeneca Coverage at Outperform - marketscreener.com
AstraZeneca stock holds after RBC starts coverage at GBP145 - ad-hoc-news.de
NEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials - Reuters
RBC Initiates AstraZeneca at Outperform With GBP145 Price Target - marketscreener.com
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study - Yahoo Finance
Amgen and AstraZeneca report survival improvement in lung cancer trial - Yahoo Finance UK
RBC Capital initiates AstraZeneca stock at Outperform, sets target at £145 By Investing.com - Investing.com Canada
RBC Initiates AstraZeneca at Outperform as Near-term Overhangs Create 'Attractive' Entry Point - marketscreener.com
Amgen and AstraZeneca report positive lung cancer trial results By Investing.com - Investing.com Nigeria
AstraZeneca stock edges lower ahead of the open after Imfinzi trial win - ad-hoc-news.de
Amgen and AstraZeneca report positive lung cancer trial results - investing.com
AstraZeneca Stock: What’s Shaping Investor Attention? - Kalkine Media
AstraZeneca stock heads into the open after a 1.2% slide - AD HOC NEWS
FDA clears Astrazeneca's Etcamah for first-line breast cancer - bioworld.com
AstraZeneca PLC : Gets a Buy rating from RBC - marketscreener.com
Astrazeneca Plc (AZN) 財務データ
収益
当期純利益
現金流量
EPS
Astrazeneca Plc (AZN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sharma Mani | See Remarks |
May 20 '26 |
Sale |
185.78 |
11,893 |
2,209,482 |
19,262 |
0.39%
1.55%
大文字化:
|
ボリューム (24 時間):